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Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system,
leading to severe neurological deficits. Current MS treatment regimens, consist of
immunomodulatory agents aiming to reduce the rate of relapses. However, these agents
are usually insufficient to treat chronic neurological disability. A promising perspective for
future therapy of MS is the regeneration of lesions with replacement of the damaged
oligodendrocytes or neurons. Therapies targeting to the enhancement of endogenous
remyelination, aim to promote the activation of either the parenchymal oligodendrocyte
progenitor cells or the subventricular zone-derived neural stem cells (NSCs). Less studied
but highly potent, is the strategy of neuronal regeneration with endogenous NSCs that
although being linked to numerous limitations, is anticipated to ameliorate cognitive
disability in MS. Focusing on the forebrain, this review highlights the role of NSCs in the
regeneration of MS lesions.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating
disease of the central nervous system (CNS) that has an important
neurodegenerative component. The pathological hallmark of MS
is the presence of demyelinating lesions (Noseworthy et al., 2000).
MS was traditionally considered as a disease affecting only the
white matter (WM) areas of the CNS; more recent studies how-
ever, showed extensive pathology also in the gray matter (GM)
(Geurts and Barkhof, 2008).
MS development is linked to loss of the blood brain barrier
(BBB) integrity and migration of autoreactive T-cells and mono-
cytes (Sospedra and Martin, 2005; Hemmer et al., 2006; Vogel
et al., 2013). Autoimmunity plays a central role in the disease
pathogenesis either as the primary cause or as the consequence
of an ongoing neurodegenerative process. Notably, several studies
in post-mortem MS brain material and experimental autoim-
mune encephalomyelitis (EAE) indicated that key features of
neurodegeneration, such as neuronal cell atrophy, axonal tran-
section, and neuronal death, already occur in early disease phases
(Trapp et al., 1998). The diffuse neuronal damage is associated
with pronounced atrophy, decreased functional connectivity and
cognitive decline in the majority of patients (Roosendaal et al.,
2010).
The major clinical subtypes of MS are relapsing-remitting
(RR) and secondary progressive (SP) MS. RR-MS represents the
initial inflammatory phase of approximately 85–90% of all cases.
SP-MS usually develops later in the disease course and is associ-
ated with axon degeneration (Lublin and Reingold, 1996). A less
common progressive subtype is primary progressive (PP)MS. PP-
MS affects approximately 10% of all cases and manifests with
no relapses but a steady decline in function from disease onset
(Andersson et al., 1999).
For treatment of MS, during the past decades, attention was
paid to the modulation of immune responses for prevention of
axon demyelination. Immunomodulatory and anti-inflammatory
agents can efficiently slow down RR-MS (and SP-MS to a certain
extent) progression by reducing the frequency of relapses (Fischer
et al., 2000; Barak and Achiron, 2002; Goodin et al., 2002).
However, they do not improve disease outcome after degenera-
tion occurs, and therefore are insufficient to treat chronic neuro-
logical disability in patients with progressive disease (Molyneux
et al., 2000; Compston and Coles, 2002; Coles et al., 2006).
It is now known, that treatment of MS requires not only pre-
vention, but also repair of the injury. Good candidates for the
repair of MS lesions are the neural stem cells (NSCs), cells that
retain their multipotential capacity in the adult and senescent
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brain (Van den Berge et al., 2010). In this review we will highlight
the importance that regenerative capacity of endogenous NSCs
has in future therapeutic options for MS.
NEURAL STEM CELLS IN THE ADULT MAMMALIAN BRAIN
NSCs are multipotent cells that have the ability to self-renew
and differentiate into neurons or glial cells (Gage, 2000). Their
production is mainly taking place at the neural tube of the devel-
oping brain (Wilson and Stice, 2006). NSCs persist in the adult
brain, albeit in much lower densities, being also present in the
brains of elderly and patients with a neurodegenerative disorder
(Leonard et al., 2009; Van den Berge et al., 2010, 2011). In the
adult brain, generation of NSCs is restricted in two highly spe-
cialized tissue niches: the subventricular zone (SVZ) of the lateral
ventricles and the subgranular zone (SGZ) of the hippocampus
(Gage et al., 1998; Quiñones-Hinojosa et al., 2007). Newborn
NSCs enter an active phase of proliferation and/or differentia-
tion once they receive stimulatory signals, such as growth factors
produced by the surrounding cells (Gage et al., 1998; Sun et al.,
2010). Differentiation of NSCs can result in the production of
new neurons with neurogenesis, or glial cells with gliogenesis.
NEUROGENESIS
Animal studies have shown that NSCs generated at the adult hip-
pocampal SGZ form new neurons which integrate in the dentate
gyrus (Cameron and Gould, 1994) whereas, NSCs generated at
the adult SVZ, form new interneurons which integrate in the
olfactory bulb (OB) (Carleton et al., 2003). The adult human SVZ
is characterized by a dense ribbon of glial fibrillary acidic protein
(GFAP) positive astrocytes that lines the lateral wall of the lateral
ventricles. This astrocyte ribbon is highly proliferative and clearly
separated from the ependyma by a hypocellular gap layer (Nader
Sanai, 2004).
New SVZ-derived neuroblasts which were differentiated from
NSCs migrate to the OB through the rostral migratory stream
(RMS) in rodents and non-human primates (Craig et al., 1999;
Pencea et al., 2001a). In this stream, migrating neuroblasts build
elongated chains that are tangentially oriented to the OB, through
glial tubes formed by astrocytes (Lois et al., 1996). In humans
however, migration of neuroblasts is elusive; studies in the early
postnatal brain described a primary corridor connecting the
infant SVZ to the OB, and a branching stream that reaches the
ventromedial prefrontal cortex (Sanai et al., 2011); studies in
the adult human brain indicated the presence of the primary
corridor only and described migration of a modest number of
neuroblasts (Van Strien et al., 2011).
In MS, neurogenesis possibly occurs at the SVZ leading to
generation of new immature neurons in a subgroup of chronic
subcortical lesions (Chang et al., 2008). However, neurogenesis in
the MS brain is reduced compared to healthy adult brain, leading
to lower neuronal supply to the OB which might explain the often
reported olfactory deficits in patients (Tepavcˇevic´ et al., 2011).
GLIOGENESIS
In the developing brain gliogenesis follows neurogenesis but
persists long after neurogenesis has ceased (Jacobson, 1991).
Differentiation of glial progenitor cells results in the for-
mation of astrocytes or oligodendrocytes (Lee et al., 2000).
Oligodendrogenesis in adulthood is restricted in and around the
SVZ and involves the formation of an intermediate progenitor
phenotype, the oligodendrocyte progenitor cell (OPC). OPCs are
self-renewing cells that can reside in multiple areas of the adult
healthy brain parenchyma until they get activated and differenti-
ated (Menn et al., 2006). Differentiation of OPCs involves expres-
sion of specific markers, changes in cellular morphology and
extension of endfeet toward the axons formyelination (Compston
et al., 1997; Blakemore and Keirstead, 1999; Young et al., 2013).
In MS, loss of axon myelin is often followed by the remyeli-
nation of nude axons with new myelin sheaths. Remyelination
is a naturally regulated process orchestrated by mature oligo-
dendrocytes (Blakemore and Keirstead, 1999). This process is
activated in response to acute demyelination and often leads to
formation of shadow plaques, areas of complete repair activity,
in otherwise intact white or gray matter. Remyelination activ-
ity is high in acute (average 80.7% of all lesions) and persists in
chronic progressive MS (average 60% of all lesions). In the WM,
remyelination occurs mainly in early inflammatory (Goldschmidt
et al., 2009) and chronic active lesions (Patani et al., 2007),
the latter being lesions surrounded by a sharp border of acti-
vated microglia/macrophages. For remyelination in MS, resident
OPCs are recruited and differentiated into mature oligodendro-
cytes (Gensert and Goldman, 1997; Nait-Oumesmar et al., 1999);
moreover, new oligodendrocyte lineage cells are produced by
a two to three-fold activation of the adult SVZ in MS (Nait-
Oumesmar et al., 2007) and EAE (Picard-Riera et al., 2002;
Tepavcˇevic´ et al., 2011).
REMYELINATION BY PARENCHYMAL OPCs IN MS
Remyelination, although activated in MS, is insufficient to repair
severe and long-lasting demyelination events like the ones occur-
ring in the progressive phases of the disease. The failure of
remyelination to sufficiently restore chronic damage is not caused
by the lesional depletion of OPCs (Wolswijk, 1998); instead,
changes that can be induced at any of the four phases consist-
ing the remyelination process, may reduce capacity of endogenous
repair in various ways that are discussed below (Franklin, 2002).
PROLIFERATION OF OPCs
In the adult demyelinating brain activated astrocytes and
microglia secrete mitogens that induce OPC proliferation, such
as the platelet-derived growth factor receptor-2A (PDGF-2A)
and fibroblast growth factor-2 (FGF-2) (Franklin and ffrench-
Constant, 2008; Clemente et al., 2013). The response of OPCs
to mitogens is regulated by the cell cycle regulatory protein p27-
Kip1 (Crockett et al., 2005) and the cyclin-dependent kinase 2
(Caillava and Baron-Van Evercooren, 2012). In MS changes in
the mitogenic environment induced by alterations in the levels
of secreted factors might inhibit proliferation of OPCs (Franklin,
2002). Modulation of growth factor levels such as the FGF-2, was
shown to enhance OPC proliferative activity in several in vitro
models (Armstrong et al., 2002; Dziembowska et al., 2005).
MIGRATION OF OPCs
Animal studies showed that inflammation and demyelination
promote migration of OPCs to the lesions (Nait-Oumesmar et al.,
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1999; Piao et al., 2013). OPCs migrate to early inflammatory
and chronic active MS lesions possibly being attracted by FGF-
2 expressed by infiltrating macrophages and microglia-derived
macrophages (Clemente et al., 2011). In chronic inactive lesions
however, formation of the characteristic glial scar composed of
hypertrophic astrocytes, limits access of OPCs to the lesion center
(Franklin and ffrench-Constant, 2008). Manipulation of chemo-
tactic pathways such as the C-X-C chemokine receptor type 4,
pharmacogenetic targets such as the FGF-2 and Anosmin-1, or
guidance cues such as semaphorin-3A and 3F, might promote
repopulation of MS lesions by OPCs, as it was shown in exper-
imental in vivo or in vitromodels for MS and in human MS brain
tissue (Williams et al., 2007; Carbajal et al., 2010; Clemente et al.,
2011).
DIFFERENTIATION OF OPCs
Demyelination influences the capacity of OPCs to differentiate
by forming a “dysregulated” signaling environment. In chronic
MS lesions, OPCs often acquire an immature phenotype which is
not permissive for axon remyelination (Wolswijk, 2000). Events
that inhibit OPC differentiation are the (1) Excessive accumu-
lation of myelin fragments (Kotter et al., 2006), (2) Deposition
of hyaluronan (Sloane et al., 2010), (3) Dysregulation of sig-
naling pathways controlling cell fate, such as the Wnt/β–catenin
(Feigenson et al., 2011) and the Notch–Jagged pathway (John
et al., 2002; Nakahara et al., 2009) and (4) Changes in levels of
growth factors or bone morphogenic proteins (Franklin, 2002;
Cheng et al., 2007). Pharmacological manipulation of therapeu-
tic targets such as leucine rich repeat and Ig domain containing
1 (Jepson et al., 2012), retinoic X receptors (Huang et al., 2011),
phosphodiesterase-7 (Medina-Rodríguez et al., 2013) and cyclin-
dependent kinase 5 (Cdk5) (Luo et al., 2014) or signaling path-
ways such as the Fyn-Rho-ROCK and protein kinase C (PKC)
(Baer et al., 2009) and the Notch/Jagged1 (Blanchard et al., 2013),
can be advantageous for the repair of MS lesions.
FUNCTION OF MATURE OLIGODENDROCYTES
In the brain of MS patients, mature oligodendrocytes may
undergo demyelination thereby losing capacity to myelinate
(Wolswijk, 2000). Moreover, demyelinated axons may lose recep-
tivity to myelination by oligodendrocytes due to re-expression of
negative regulators, such as the polysialylated neural cell-adhesion
molecule (PSA-NCAM) (Charles et al., 2002). These two or other
events such as the reported reduction in astrocytic expression of
neuregulins (Viehover et al., 2001) or the increased expression
of insulin-like growth factor (IGF) binding proteins by oligoden-
drocytes (Wilczak et al., 2008), might prevent restoration of axon
conduction properties in MS lesions. Pharmacological interven-
tions to reverse those events might prove efficient in promoting
repair of MS lesions (Lundgaard et al., 2013).
REGENERATION BY NEW CELLS IN MS
TARGETING OLIGODENDROCYTE REGENERATION
Since sufficient levels of remyelination can repair damaged
axons, stimulation of endogenous activity might be beneficial for
repair of MS lesions. Besides activation of parenchymal OPCs,
generation of new oligodendrocytes for the increase of brain
remyelination activity appears a promising perspective for future
therapies. This can be achieved with engraftment of transplanted
cells or with stimulation of SVZ-derived NSCs by transplanted
cells or growth factors to induce differentiation into OPCs.
Stimulation of endogenous NSCs with cell transplantation
Transplanted stem cells can boost remyelination by cell replace-
ment or bystander neuroprotection and/or immunomodulation
(Pluchino and Martino, 2008). Bystander effects induced by
transplanted cells were shown to promote migration, differen-
tiation and/or survival of endogenous NSCs thereby enhancing
self-repair. The ideal cell types for transplantation in animal mod-
els of demyelination are the NSCs and mesenchymal stem cells
(MSCs), while two other possible cell sources are the embry-
onic and induced pluripotent stem cells (iPSCs). The route of
administration is an important factor determining the effect type
andmagnitude that cell transplantation induces. Mostly preferred
routes for the delivery of MSCs or NSCs are the intravenous and
intrathecal injections (Gianvito Martino, 2010). Administration
of autologous MSCs in patients with progressive MS was shown
to improve clinical outcome based on magnetic resonance imag-
ing (MRI) examination while reported adverse effects were not
significant (Laroni et al., 2013).
Stimulation of endogenous NSCs with growth factors
The new thrust in the treatment of MS is grounded on the dis-
covery that NSCs persist within the adult healthy brain. The
human SVZ is located at the lateral wall of the lateral ven-
tricles, thereby providing an accessible route for the intracere-
broventricular delivery of growth factors to activate NSC prolif-
eration/differentiation. Newborn cells may theoretically replace
the old damaged ones and promote repair in areas with poor
regeneration. Intracerebroventricular application of growth fac-
tors have revealed multiple beneficial effects in EAE (Tafreshi,
2006).
The regeneration of MS lesions with new oligodendrocytes
depends on the stage and location of the lesion. Although the role
of inflammation in remyelination has not yet been clarified, our
speculation is that repair of small newly-formed lesions might be
advantageous over the repair of chronic lesions, in terms of repar-
ative efficiency and energy consumption. Periventricular lesions
are often present in MS and analyses of such lesions showed
enhanced number of pro-migratory adhesion molecule PSA-
NCAM+ progenitors expressing Sox9, Sox10, and/or Olig2mark-
ers of glial fate. Concomitant enhancement of the PSA-NCAM+
progenitor population at the proximal SVZ suggested increased
oligodendrogenesis (Nait-Oumesmar et al., 2007). These pieces
of evidence indicate that regeneration of oligodendrocytes might
be efficient in repairing lesions located near the SVZ, such as
the corpus callosum (Figure 1). In accordance, recent evidence
showed a four-fold increase in the number of NSC-derived oligo-
dendrocytes expressing the PDGF receptor α and Olig2 markers
of oligodendrocytes, in a single demyelinating lesion within the
corpus callosum (Menn et al., 2006).
Interventions to modulate growth factor signaling for promot-
ing oligodendrocyte replacement and remyelination are nowadays
the focus of intense study. Both in vivo and in vitro experiments
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FIGURE 1 | Model strategy for regeneration of MS lesions via
activation of adult SVZ-derived NSCs. Stimulation of neural stem
cells (NSCs) via intracerebroventricular administration of, e.g.,
growth factors may lead to the regeneration of newly formed
lesions which are located in white matter (WM) or gray matter
(GM) areas nearby the subventricular zone (SVZ) of the multiple
sclerosis (MS) brain (A) such as the adjacent corpus callosum
(CC) (B) and the cingulate gyrus (C).
Table 1 | Factors and secreted molecules activating the adult SVZ-derived NSCs, in animal models of demyelination.
Factor Model Process Function References
HB-EGF LPC demyelinated mouse O Recruitment Cantarella et al., 2008
FGF-2 Cell culture O Recruitment Clemente et al., 2011
CNTF LPC demyelinated rodent O Recruitment Vernerey et al., 2013
NGF EAE rat O Differentiation Aloe and Micera, 1998
IGF-1 Cell culture N Differentiation Brooker et al., 2000
PEDF Transgenic mouse O Fate commitment Sohn et al., 2012
PDGF Transgenic mouse O Proliferation Jackson et al., 2006
VEGF Unlesioned rat N Proliferation Jin et al., 2002
BDNF Unlesioned rat N Proliferation Pencea et al., 2001b
MOLECULE
Reelin LPC demyelinated mouse N Recruitment Courtès et al., 2011
Netrin 1 LPC demyelinated mouse O Recruitment Cayre et al., 2013
Chordin LPC demyelinated mouse O Recruitment Jablonska et al., 2010
Noggin Cuprizone demyelinated mouse O Proliferation Cate et al., 2010
Fate commitment
LPC, Lysolecithin; O, Oligodendrogenesis; N, Neurogenesis; EAE, experimental autoimmune encephalomyelitis; HB-EGF, Heparin-binding epidermal growth factor;
FGF-2, Fibroblast growth factor 2, CNTF; Ciliary neurotrophic factor; NGF, Nerve growth factor; IGF-1, Insulin-like growth factor 1; PEDF, Pigment epithelium-derived
factor; PDGF, Platelet-derived growth factor; VEGF, Vascular endothelial growth factor; BDNF, Brain-derived neurotrophic factor.
revealed various factors which act on OPCs derived by the adult
SVZ, and influence proliferation, migration or differentiation
properties (Table 1). An advanced candidate for MS is IGF-1, a
factor previously shown to delay EAE onset and improve clinical
outcome (Zhang et al., 2011). In a pilot trial, seven MS patients
were treated with subcutaneous administration of recombinant
(rh) IGF-1 over a 6-month period of time. The peripheral admin-
istration of rhIGF-1 had no significant adverse effects. However,
MRI examination of patients after treatment showed no sig-
nificant clinical improvement. Explanations for the absence of
positive effects on clinical outcome were the small sample size
and the limited penetration of rhIGF-1 across the BBB (Frank
et al., 2002). Since surgically invasive procedures are not appli-
cable in human trials, intranasal administration of growth factors
might represent an interesting alternative approach for successful
delivery inside the CNS (Hanson and Frey, 2008).
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TARGETING NEURONAL REGENERATION
The confirmed existence of OPCs in the adult brain as well as
the increasing understanding of the pathways regulating endoge-
nous remyelination, are the basic reasons why regeneration of
oligodendrocytes is a more well investigated approach compared
to regeneration of neurons. Replacement of damaged neurons
however, is anticipated to offer intriguing possibilities for the
rehabilitation of cognitive disturbances in patients with progres-
sive MS. New neurons may repopulate focal sites of degeneration
located near the SVZ, such as the OB or the cingulate gyrus, to
induce repair, contributing to the re-growth of nerves that have
been lost (Figure 1).
Challenges associated with that strategy are linked to the type,
density and ability of new neurons to integrate into defined cir-
cuits. Acquisition of specific neuronal subtypes is a demanding
step for neuronal regeneration ofMS lesions since recent evidence
indicated heterogeneity and reduced neuropotency in the popu-
lation of adult SVZ-derived NSCs (Shen et al., 2006). Moreover,
the ability of new neurons to functionally mature at the sites
of damage is still debated because the sites of lesions are nor-
mally non-neurogenic (Obernier et al., 2014). For the expansion
of new neurons, and promotion of maturation, specific growth
factors can be administered at the SVZ (Table 1). The possibility
that new neurons are poorly myelinated due to lack of oligo-
dendrocytes has to be studied. Importantly, the extraordinary
proliferation or direction of SVZ-derived NSCs toward neuronal
phenotypes other than the ones they were intrinsically commit-
ted for might induce unwanted effects linked to tumorigenesis.
Monitoring and quantification of NSC activation is required
and can be conducted with non-invasive techniques, such as the
positron emission tomography (Rueger et al., 2010).
CONCLUSION
Stimulation of endogenous NSCs with growth factors is an inter-
esting approach for treatment of MS and requires more research
in order to reveal its entire therapeutic potential. An important
question that needs to be addressed is if this approach can repair
all or subtypes of MS lesions depending on whether the damage is
focal or diffuse. Notably, MS is a complex disease showing activ-
ity even in late progressive phases. Therefore, even if regeneration
with NSCs proves efficient to revert damage in the CNS of MS
patients that today is considered to be irreversible, a combina-
tion with disease modifying agents might be needed to halt MS
progression.
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